Research programme: gemcitabine-cardiolipin conjugate - Insys Therapeutics

Drug Profile

Research programme: gemcitabine-cardiolipin conjugate - Insys Therapeutics

Alternative Names: Gemcitabine-cardiolipin conjugate; NEO-6002

Latest Information Update: 19 Oct 2016

Price : $50

At a glance

  • Originator NeoPharm Inc
  • Developer INSYS Therapeutics, Inc
  • Class Drug conjugates; Lipids; Pyrimidine nucleosides
  • Mechanism of Action DNA synthesis inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer

Most Recent Events

  • 23 Mar 2005 Preclinical trials in Cancer in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top